TEVA Stock Analysis: Teva Pharma Industries | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 48.809m USD | 12M Return: 72.1% | IL0006290147 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 268M
EPS Trend: 69.0%
Qual. Beats: 0
Rev. Trend: 93.5%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Teva Pharmaceutical Industries is an Israeli-based global pharmaceutical company that develops, manufactures, and markets both generic medicines and branded biopharmaceutical products across the United States, Europe, Israel, and other international markets. Founded in 1901 and headquartered in Tel Aviv-Yafo, the company operates one of the worlds largest generic drug portfolios, offering medicines in tablets, capsules, injectables, inhalants, and other dosage forms, alongside active pharmaceutical ingredients and contract manufacturing services.
The companys branded biopharmaceutical business focuses on central nervous system (CNS), respiratory, and oncology therapeutics, with key products including COPAXONE for multiple sclerosis, AJOVY for migraine prevention, AUSTEDO for tardive dyskinesia and Huntingtons chorea, UZEDY for schizophrenia, and BENDEKA/TREANDA for certain leukemia and lymphoma indications. Teva also markets respiratory products such as QVAR RediHaler, ProAir RespiClick, and AirDuo RespiClick, and operates an out-licensing platform that monetizes its product portfolio through partnerships with other pharmaceutical companies.
The generic drug industry is characterized by intense price competition and ongoing consolidation, while the specialty/branded biopharmaceutical segment typically carries higher margins and longer product life cycles through patent protection. Teva maintains collaboration and licensing agreements with partners including MedinCell, Sanofi, Alvotech, Biolojic Design, and MODAG, supporting its dual business model of high-volume generics and higher-margin specialty therapeutics.
- Austedo sales surge offset Copaxone generic erosion
- Debt reduction accelerates as free cash flow expands
- Opioid litigation settlement costs pressure margins
| Net Income: 506.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: -4.78% < 20% (prev 7.42%; Δ -12.20% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.77b > Net Income 506.0m |
| Net Debt (13.2b) to EBITDA (2.04b): 6.47 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago 1.63% < -2% |
| Gross Margin: 53.50% > 18% (prev 50.09%; Δ 3.41% > 0.5%) |
| Asset Turnover: 43.13% > 50% (prev 42.09%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 1.21 > 6 (EBIT TTM 1.05b / Interest Expense TTM 867.0m) |
| A: -0.02 (Total Current Assets 14.6b - Total Current Liabilities 15.4b) / Total Assets 40.0b |
| B: -0.34 (Retained Earnings -13.7b / Total Assets 40.0b) |
| C: 0.03 (EBIT TTM 1.05b / Avg Total Assets 39.9b) |
| D: 0.25 (Book Value of Equity 7.98b / Total Liabilities 32.1b) |
| Altman-Z'' = -0.82 = CCC |
| DSRI: 0.98 (Receivables 3.84b/3.81b, Revenue 17.2b/16.8b) |
| GMI: 0.94 (GM 50.09% / 53.50%) |
| AQI: 0.97 (AQ_t 0.53 / AQ_t-1 0.55) |
| SGI: 1.03 (Revenue 17.2b / 16.8b) |
| TATA: -0.03 (NI 506.0m - CFO 1.77b) / TA 40.0b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of November 12, 2026, the stock is trading at USD 43.24 with a total of 9,547,129 shares traded. Over the past week, the price has changed by +3.32%, over one month by +5.03%, over three months by +18.53% and over the past year by +72.07%.
Current recommended Stop Loss: 39.90 (which is 7.7% or 2.7 ATR below the current price).
Teva Pharma Industries has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy TEVA.
- StrongBuy: 8
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.9 | 13.2% |
P/E Trailing = 97.3256
P/E Forward = 12.5471
P/S = 2.8328
P/B = 5.8197
P/EG = 0.7131
Revenue TTM = 17.2b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 2.04b USD
Long Term Debt = 12.7b USD (from longTermDebt, last quarter)
Short Term Debt = 4.04b USD (from shortTermDebt, last quarter)
Debt = 17.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 266.0m
Net Debt = 13.2b USD (calculated: Debt 17.2b - CCE 4.08b)
Enterprise Value = 62.0b USD (48.8b + Debt 17.2b - CCE 4.08b)
Interest Coverage Ratio = 1.21 (Ebit TTM 1.05b / Interest Expense TTM 867.0m)
EV/FCF = 50.14x (Enterprise Value 62.0b / FCF TTM 1.24b)
FCF Yield = 1.99% (FCF TTM 1.24b / Enterprise Value 62.0b)
FCF Margin = 7.17% (FCF TTM 1.24b / Revenue TTM 17.2b)
Net Margin = 2.94% (Net Income TTM 506.0m / Revenue TTM 17.2b)
Gross Margin = 53.50% ((Revenue TTM 17.2b - Cost of Revenue TTM 8.01b) / Revenue TTM)
Gross Margin QoQ = 55.52% (prev 51.98%)
Tobins Q-Ratio = 1.55 (Enterprise Value 62.0b / Total Assets 40.0b)
Interest Expense / Debt = 5.03% (Interest Expense 867.0m / Debt 17.2b)
Taxrate = 22.0% (66.0m / 300.0m)
NOPAT = 819.0m (EBIT 1.05b * (1 - 22.00%))
Current Ratio = 0.95 (Total Current Assets 14.6b / Total Current Liabilities 15.4b)
Debt / Equity = 2.16 (Debt 17.2b / totalStockholderEquity, last quarter 7.98b)
Debt / EBITDA = 6.47 (Net Debt 13.2b / EBITDA 2.04b)
Debt / FCF = 10.65 (Net Debt 13.2b / FCF TTM 1.24b)
Total Stockholder Equity = 7.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.27% (Net Income 506.0m / Total Assets 40.0b)
RoE = 6.35% (Net Income TTM 506.0m / Total Stockholder Equity 7.97b)
RoCE = 5.09% (EBIT 1.05b / Capital Employed (Equity 7.97b + L.T.Debt 12.7b))
RoIC = 2.95% (NOPAT 819.0m / Invested Capital 27.8b)
WACC = 5.77% (E(48.8b)/V(66.1b) * Re(6.43%) + D(17.2b)/V(66.1b) * Rd(5.03%) * (1-Tc(0.22)))
Discount Rate = 6.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.96 | Cagr: 1.94%
[DCF] Terminal Value 77.97% ; FCFF base≈972.8m ; Y1≈1.12b ; Y5≈1.64b
[DCF] Fair Price = 9.89 (EV 24.7b - Net Debt 13.2b = Equity 11.5b / Shares 1.17b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 69.04 | EPS CAGR: 4.72% | SUE: 0.64 | # QB: 0
Revenue Correlation: 93.54 | Revenue CAGR: 3.20% | SUE: 1.11 | # QB: 1
EPS current Quarter (2027-03-31): EPS=0.63 | Chg30d=+0.49% | Revisions=-25% | Analysts=9
EPS current Year (2026-12-31): EPS=2.06 | Chg30d=-3.93% | Revisions=+0% | GrowthEPS=-29.5% | GrowthRev=-2.9%
EPS next Year (2027-12-31): EPS=3.11 | Chg30d=+0.74% | Revisions=+0% | GrowthEPS=+50.9% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -17% (up=1, down=2)